MX385289B - Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk). - Google Patents

Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk).

Info

Publication number
MX385289B
MX385289B MX2019000744A MX2019000744A MX385289B MX 385289 B MX385289 B MX 385289B MX 2019000744 A MX2019000744 A MX 2019000744A MX 2019000744 A MX2019000744 A MX 2019000744A MX 385289 B MX385289 B MX 385289B
Authority
MX
Mexico
Prior art keywords
crystal
ttk
inhibitor
solid forms
threonine kinase
Prior art date
Application number
MX2019000744A
Other languages
English (en)
Other versions
MX2019000744A (es
Inventor
Heinz W Pauls
Peter Brent Sampson
Sze- Wan Li
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of MX2019000744A publication Critical patent/MX2019000744A/es
Publication of MX385289B publication Critical patent/MX385289B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54Organic compounds
    • C30B29/58Macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/02Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/14Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Metallurgy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a un novedoso co-cristal del compuesto de formula (I): (Formula (I)) en donde la molecula co-formadora es hemihidrato de bifosfato, a procesos para la preparacion del co-cristal, a composiciones farmaceuticas que contienen el co-cristal, al uso de tal co-cristal en la manufactura de un medicamento para uso en el tratamiento de cancer y a métodos para tratar tales enfermedades en el cuerpo humano o animal por administracion de una cantidad terapeuticamente efectiva de tal co-cristal.
MX2019000744A 2016-07-18 2017-07-13 Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk). MX385289B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662363424P 2016-07-18 2016-07-18
PCT/CA2017/050848 WO2018014116A1 (en) 2016-07-18 2017-07-13 Solid forms of ttk inhibitor

Publications (2)

Publication Number Publication Date
MX2019000744A MX2019000744A (es) 2019-05-02
MX385289B true MX385289B (es) 2025-03-18

Family

ID=60991755

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019000744A MX385289B (es) 2016-07-18 2017-07-13 Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk).
MX2021008658A MX2021008658A (es) 2016-07-18 2019-01-17 Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021008658A MX2021008658A (es) 2016-07-18 2019-01-17 Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk).

Country Status (26)

Country Link
US (3) US10584130B2 (es)
EP (1) EP3484888B1 (es)
JP (2) JP6961675B2 (es)
KR (2) KR102700233B1 (es)
CN (2) CN109476667B (es)
AU (2) AU2017299850B2 (es)
BR (1) BR112019000813A2 (es)
CA (1) CA3030230A1 (es)
DK (1) DK3484888T3 (es)
ES (1) ES2945108T3 (es)
FI (1) FI3484888T5 (es)
HR (1) HRP20230481T1 (es)
HU (1) HUE061872T2 (es)
IL (1) IL264173B2 (es)
LT (1) LT3484888T (es)
MA (1) MA45691A (es)
MX (2) MX385289B (es)
PL (1) PL3484888T3 (es)
PT (1) PT3484888T (es)
RS (1) RS64210B1 (es)
RU (2) RU2753905C2 (es)
SG (2) SG10202103332UA (es)
SI (1) SI3484888T1 (es)
SM (1) SMT202300156T1 (es)
TW (2) TWI745400B (es)
WO (1) WO2018014116A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385289B (es) 2016-07-18 2025-03-18 Univ Health Network Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk).
KR20240175121A (ko) 2023-06-12 2024-12-19 한국재료연구원 희토류 산화물을 이용한 입계확산물질의 제조방법 및 이를 이용한 R-Fe-B계 영구자석의 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068444A1 (en) 2001-02-21 2002-09-06 Chiron Corporation Ttk in diagnosis and as a therapeutic target in cancer
DK1812440T3 (da) * 2004-11-04 2011-01-31 Vertex Pharma Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
EP2651948A1 (en) * 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
AU2013344716B2 (en) 2012-11-16 2018-03-01 University Health Network Pyrazolopyrimidine compounds
EA029372B1 (ru) * 2013-11-15 2018-03-30 Юниверсити Хелс Нетуорк Пиразолопиримидиновые соединения
MX385289B (es) 2016-07-18 2025-03-18 Univ Health Network Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk).

Also Published As

Publication number Publication date
MX2019000744A (es) 2019-05-02
JP2019521155A (ja) 2019-07-25
AU2017299850B2 (en) 2021-05-27
SG11201900113UA (en) 2019-02-27
PL3484888T3 (pl) 2023-06-26
RU2753905C2 (ru) 2021-08-24
MA45691A (fr) 2019-05-22
MX2021008658A (es) 2021-08-19
SG10202103332UA (en) 2021-05-28
CN115093416A (zh) 2022-09-23
TWI745400B (zh) 2021-11-11
RU2019101109A (ru) 2020-08-18
NZ749844A (en) 2024-03-22
US11104681B2 (en) 2021-08-31
EP3484888B1 (en) 2023-02-22
CA3030230A1 (en) 2018-01-25
AU2017299850A8 (en) 2019-03-21
HRP20230481T1 (hr) 2023-07-21
ES2945108T3 (es) 2023-06-28
BR112019000813A2 (pt) 2019-04-30
FI3484888T5 (fi) 2024-02-26
HUE061872T2 (hu) 2023-08-28
JP2022001598A (ja) 2022-01-06
EP3484888A1 (en) 2019-05-22
IL264173B2 (en) 2025-05-01
DK3484888T3 (da) 2023-05-30
KR102537088B1 (ko) 2023-05-25
US20190292193A1 (en) 2019-09-26
SI3484888T1 (sl) 2023-07-31
EP3484888A4 (en) 2020-01-08
RU2021124795A (ru) 2021-09-14
AU2021221447B2 (en) 2023-09-21
JP7263473B2 (ja) 2023-04-24
US20200270259A1 (en) 2020-08-27
TW201803876A (zh) 2018-02-01
PT3484888T (pt) 2023-05-26
FI3484888T3 (fi) 2023-05-03
CN115093416B (zh) 2024-04-12
KR102700233B1 (ko) 2024-08-28
CN109476667A (zh) 2019-03-15
SMT202300156T1 (it) 2023-07-20
RS64210B1 (sr) 2023-06-30
KR20230074839A (ko) 2023-05-31
TW202202507A (zh) 2022-01-16
US11878980B2 (en) 2024-01-23
IL264173B1 (en) 2025-01-01
CN109476667B (zh) 2022-06-28
KR20190029601A (ko) 2019-03-20
IL264173A (en) 2019-02-28
RU2019101109A3 (es) 2021-02-05
WO2018014116A1 (en) 2018-01-25
AU2017299850A1 (en) 2019-01-24
US10584130B2 (en) 2020-03-10
US20220089601A1 (en) 2022-03-24
LT3484888T (lt) 2023-06-12
TWI824313B (zh) 2023-12-01
JP6961675B2 (ja) 2021-11-05
AU2021221447A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
GEP20257823B (en) Amino quinazoline derivatives as p2x3 inhibitors
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
EA201790088A1 (ru) Ингибиторы syk
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
EA201790660A1 (ru) Ингибитор киназ
SA521422152B1 (ar) Vanin مركبات عطرية غير متجانسة كمثبطات
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
EA201992152A1 (ru) Химические соединения
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
PH12016502353A1 (en) Pharmaceutical composition
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX2019001579A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
BR112022010181A2 (pt) Composto tri-heterocíclico como inibidor de jak e uso do mesmo
MX2019007213A (es) Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina.
MX385289B (es) Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk).
EA202191477A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
BR112017015474A2 (pt) inibidores de bace1
MX2019007360A (es) Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina.